That was an easy one to screw up. The results coul

That was an easy one to screw up. The results could be read at least two different ways, and nobody would know for sure until the company clarified. But it doesn’t really matter because both outcomes are extremely favorable to the potential of Leronlimab. The other way around is more flashy and definitive, but almost hitting p-value in a very small sample size like that is about as strong an indicator of success in a larger trial that you can get.